SC
FRTX

Steven Cohen’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Steven Cohen’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed -$1 – 2930
2023
Q1 		$1 Buy
+1
New +$2 ﹤0.01% 2186

Other funds holding FRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Steven Cohen's FRTX Position: Q2 2023 in Review

Steven Cohen sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2023, closing a stake of 1 share — an estimated $1 sold.

Steven Cohen first reported a position in FRTX in Q1 2023 and held it in 1 quarter. The position peaked at $1 in Q1 2023. 15 funds tracked by Wall St. Rank hold FRTX as of Q2 2023.

  • Steven Cohen reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Steven Cohen sold 1 Fresh Tracks Therapeutics, Inc. Common Stock share in Q2 2023, an estimated $1.
  • Steven Cohen first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Steven Cohen's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1 in Q1 2023.
  • 15 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Point72 Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.